Krystal Retained Earnings from 2010 to 2024
| KRYS Stock | USD 164.10 0.32 0.20% |
Retained Earnings | First Reported 2016-12-31 | Previous Quarter -269.8 M | Current Value -268.9 M | Quarterly Volatility 115.1 M |
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 6.2 M, as well as many exotic indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
Krystal | Retained Earnings |
Latest Krystal Biotech's Retained Earnings Growth Pattern
Below is the plot of the Retained Earnings of Krystal Biotech over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Krystal Biotech's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (269.83 M) | 10 Years Trend |
|
Retained Earnings |
| Timeline |
Krystal Retained Earnings Regression Statistics
| Arithmetic Mean | (73,003,043) | |
| Coefficient Of Variation | (148.40) | |
| Mean Deviation | 87,425,797 | |
| Median | (9,070,000) | |
| Standard Deviation | 108,333,034 | |
| Sample Variance | 11736T | |
| Range | 279.6M | |
| R-Value | (0.83) | |
| Mean Square Error | 3838.6T | |
| R-Squared | 0.70 | |
| Significance | 0.0001 | |
| Slope | (20,213,348) | |
| Total Sum of Squares | 164304.6T |
Krystal Retained Earnings History
Other Fundumenentals of Krystal Biotech
Krystal Biotech Retained Earnings component correlations
Click cells to compare fundamentals
About Krystal Biotech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Krystal Biotech income statement, its balance sheet, and the statement of cash flows. Krystal Biotech investors use historical funamental indicators, such as Krystal Biotech's Retained Earnings, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may use each financial statement separately, they are all related. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Krystal Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Krystal Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Krystal Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -269.8 M | -256.3 M | |
| Retained Earnings Total Equity | -126.7 M | -120.4 M |
Pair Trading with Krystal Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Krystal Stock
| 0.69 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Krystal Stock
| 0.79 | PTN | Palatin Technologies Financial Report 21st of May 2024 | PairCorr |
| 0.54 | MYMD | MyMD Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Krystal Biotech Correlation against competitors. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.18 | Revenue Per Share 3.451 | Return On Assets (0.05) | Return On Equity 0.0887 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.